BACKGROUND: With the exception of APOE epsilon4 allele, the common genetic risk factors for sporadic Alzheimer's Disease (AD) are unknown. METHODS AND FINDINGS: We completed a genome-wide association study on 381 participants in the ADNI (Alzheimer's Disease Neuroimaging Initiative) study. Samples were genotyped using the Illumina Human610-Quad BeadChip. 516,645 unique Single Nucleotide Polymorphisms (SNPs) were included in the analysis following quality control measures. The genotype data and raw genetic data are freely available for download (LONI, http://www.loni.ucla.edu/ADNI/Data/). Two analyses were completed: a standard case-control analysis, and a novel approach using hippocampal atrophy measured on MRI as an objectively defined, quantitative phenotype. A General Linear Model was applied to identify SNPs for which there was an interaction between the genotype and diagnosis on the quantitative trait. The case-control analysis identified APOE and a new risk gene, TOMM40 (translocase of outer mitochondrial membrane 40), at a genome-wide significance level of < or =10(-6) (10(-11) for a haplotype). TOMM40 risk alleles were approximately twice as frequent in AD subjects as controls. The quantitative trait analysis identified 21 genes or chromosomal areas with at least one SNP with a p-value < or =10(-6), which can be considered potential "new" candidate loci to explore in the etiology of sporadic AD. These candidates included EFNA5, CAND1, MAGI2, ARSB, and PRUNE2, genes involved in the regulation of protein degradation, apoptosis, neuronal loss and neurodevelopment. Thus, we identified common genetic variants associated with the increased risk of developing AD in the ADNI cohort, and present publicly available genome-wide data. Supportive evidence based on case-control studies and biological plausibility by gene annotation is provided. Currently no available sample with both imaging and genetic data is available for replication. CONCLUSIONS: Using hippocampal atrophy as a quantitative phenotype in a genome-wide scan, we have identified candidate risk genes for sporadic Alzheimer's disease that merit further investigation.
BACKGROUND: With the exception of APOE epsilon4 allele, the common genetic risk factors for sporadic Alzheimer's Disease (AD) are unknown. METHODS AND FINDINGS: We completed a genome-wide association study on 381 participants in the ADNI (Alzheimer's Disease Neuroimaging Initiative) study. Samples were genotyped using the Illumina Human610-Quad BeadChip. 516,645 unique Single Nucleotide Polymorphisms (SNPs) were included in the analysis following quality control measures. The genotype data and raw genetic data are freely available for download (LONI, http://www.loni.ucla.edu/ADNI/Data/). Two analyses were completed: a standard case-control analysis, and a novel approach using hippocampal atrophy measured on MRI as an objectively defined, quantitative phenotype. A General Linear Model was applied to identify SNPs for which there was an interaction between the genotype and diagnosis on the quantitative trait. The case-control analysis identified APOE and a new risk gene, TOMM40 (translocase of outer mitochondrial membrane 40), at a genome-wide significance level of < or =10(-6) (10(-11) for a haplotype). TOMM40 risk alleles were approximately twice as frequent in AD subjects as controls. The quantitative trait analysis identified 21 genes or chromosomal areas with at least one SNP with a p-value < or =10(-6), which can be considered potential "new" candidate loci to explore in the etiology of sporadic AD. These candidates included EFNA5, CAND1, MAGI2, ARSB, and PRUNE2, genes involved in the regulation of protein degradation, apoptosis, neuronal loss and neurodevelopment. Thus, we identified common genetic variants associated with the increased risk of developing AD in the ADNI cohort, and present publicly available genome-wide data. Supportive evidence based on case-control studies and biological plausibility by gene annotation is provided. Currently no available sample with both imaging and genetic data is available for replication. CONCLUSIONS: Using hippocampal atrophy as a quantitative phenotype in a genome-wide scan, we have identified candidate risk genes for sporadic Alzheimer's disease that merit further investigation.
Authors: C R Jack; M Slomkowski; S Gracon; T M Hoover; J P Felmlee; K Stewart; Y Xu; M Shiung; P C O'Brien; R Cha; D Knopman; R C Petersen Journal: Neurology Date: 2003-01-28 Impact factor: 9.910
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: Jonathan H Morra; Zhuowen Tu; Liana G Apostolova; Amity E Green; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Arthur W Toga; Clifford R Jack; Norbert Schuff; Michael W Weiner; Paul M Thompson Journal: Neuroimage Date: 2008-11-08 Impact factor: 6.556
Authors: A J Saykin; H A Wishart; L A Rabin; R B Santulli; L A Flashman; J D West; T L McHugh; A C Mamourian Journal: Neurology Date: 2006-09-12 Impact factor: 9.910
Authors: Giovanni B Frisoni; Michela Pievani; Cristina Testa; Francesca Sabattoli; Lorena Bresciani; Matteo Bonetti; Alberto Beltramello; Kiralee M Hayashi; Arthur W Toga; Paul M Thompson Journal: Brain Date: 2007-02-09 Impact factor: 13.501
Authors: Lynn M Bekris; Nichole M Galloway; Thomas J Montine; Gerard D Schellenberg; Chang-En Yu Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-03-05 Impact factor: 3.568
Authors: Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Andrew J Saykin; Li Shen; Tatiana M Foroud; Steven G Potkin; Shanker Swaminathan; Sungeun Kim; Shannon L Risacher; Kwangsik Nho; Matthew J Huentelman; David W Craig; Paul M Thompson; Jason L Stein; Jason H Moore; Lindsay A Farrer; Robert C Green; Lars Bertram; Clifford R Jack; Michael W Weiner Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Anita Lakatos; Olga Derbeneva; Danny Younes; David Keator; Trygve Bakken; Maria Lvova; Marty Brandon; Guia Guffanti; Dora Reglodi; Andrew Saykin; Michael Weiner; Fabio Macciardi; Nicholas Schork; Douglas C Wallace; Steven G Potkin Journal: Neurobiol Aging Date: 2010-06-11 Impact factor: 4.673
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2011-11-02 Impact factor: 21.566
Authors: Valerie Valant; Brendan T Keenan; Christopher D Anderson; Joshua M Shulman; William J Devan; Alison M Ayres; Kristin Schwab; Joshua N Goldstein; Anand Viswanathan; Steven M Greenberg; David A Bennett; Philip L De Jager; Jonathan Rosand; Alessandro Biffi Journal: Transl Stroke Res Date: 2012-04-12 Impact factor: 6.829
Authors: Lei Du; Kefei Liu; Xiaohui Yao; Shannon L Risacher; Junwei Han; Andrew J Saykin; Lei Guo; Li Shen Journal: Med Image Anal Date: 2020-01-23 Impact factor: 8.545
Authors: Caroline M Nievergelt; Allison E Ashley-Koch; Shareefa Dalvie; Michael A Hauser; Rajendra A Morey; Alicia K Smith; Monica Uddin Journal: Biol Psychiatry Date: 2018-02-02 Impact factor: 13.382